AGL

Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

agilon Health delivered a strong Q2 2026 with revenue of $1.49B, a $250M YoY medical margin swing, and raised FY26 guidance across all key metrics. AGL's operational turnaround is supported by improved cost trends, enhanced data pipelines, and clinical pathway execution, notably reducing inpatient first-diagnosis rates from 25% to under 5%. Balance sheet strength is evident with over $220M net cash, while disciplined membership management supports ongoing profitability.

Agilon Health NYSE: AGL reported second-quarter results that exceeded its guidance for medical margin and adjusted EBITDA, citing stronger risk-adjustment revenue, favorable medical-cost development and progress in its clinical and quality initiatives. The company also raised its full-year 2026 outlook.

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the second quarter ended June 30, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence i.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Agilon Health, Inc. (NYSE: AGL) (“Agilon”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/agilon-health/ Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company's stock between April 15, 2021 and February 27, 2024. According to the complaint, during that.

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 after market close on Wednesday, August 5, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 439-1904 for U.S. participants and +1 (585) 542-9983 for international participants and refe.

Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.